TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03055286
Drug: CWP232291
Approvals — FDA: no, EMA: no, PMDA: no
Description: For cohort 1-3, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 5 following CWP232291 infusion.~For cohort 4, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 7 following 250 mg/m2 CWP232291 infusion.
Study: NCT04264897
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicified microcrystalline cellulose, Micosolle®, K30 povidone, sodium starch glycolate, and magnesium stearate
Study: NCT03920644
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Patch, 1 patch behind the ear.
Study: NCT03920644
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Gel,up to 6 administration of intranasal gel.
Study: NCT03439488
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo as oral tablets will be administered in Parts 1, 2 and 3.
Study: NCT01584544
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Study: NCT01584544
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Study: NCT01584544
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral pills, 1350mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Study: NCT01584544
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Study: NCT01584544
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral pills, 1650mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Study: NCT00318409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01078818
Drug: Oral and intravenous Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative Period:1oral placebo/24h Postoperative Period:200cc physiologic solution iv placebo /24-48h x 3 dosis + 1oral placebo/24h One month Follow-up:1 oral placebo/24h
Study: NCT03577431
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg/kg administered intravenously (IV) within 24 to 72 hours prior to Treg product (arTreg-CSB) infusion.
Study: NCT01060007
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01060007
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00081978
Drug: TMC125
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01654211
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single iv infusion
Study: NCT00858611
Drug: Flulaval (Registered) Seasonal Influenza Vaccine
Normalized name: Flulaval 2024-2025
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03165253
Drug: Bifidobacterium Animalis Oral Product
Normalized name: Bifidobacterium animalis Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The synbiotic group will receive this product.
Study: NCT03165253
Drug: Clarithromycin Oral Tablet
Normalized name: clarithromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg/day B.I.D.
Study: NCT00417820
Drug: BCT194
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01394120
Drug: Targeted Therapy Tailored Treatment
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy tailored treatment, based on molecular determination in pancreas cancer specimen~* Tim Synthase (TS) (neg), ERCC-1 (neg), Topoisomerase I (Topo I) (pos) : FOLFIRINOX~* TS (neg), ERCC-1 (neg), Topo I (neg): FOLFOX~* TS (neg), ERCC-1 (pos), Topo I (pos): FOLFIRI~* TS (neg), ERCC-1 (pos), Topo I (neg): Capecitabine/Gemcitabine~* TS (pos), EGFR Not Amplificate, K-Ras Mutation (pos) : Gemcitabine single agent~* TS (pos), EGFR Ampl or K-Ras mut (neg): Gemcitabine plus Erlotinib
Study: NCT01394120
Drug: Standard Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients treated based on investigator´s criteria: : FOLFIRINOX, FOLFOX, FOLFIRI, Capecitabine-Gemcitabine, Erlotinib-Gemcitabine or Gemcitabine single agent
Study: NCT01036594
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 20mg po qam and 10mg po qpm~If participant has ≥30% PSA decline at 12 week evaluation, treatment continues until progressive disease (by RECIST criteria OR by PSAWG criteria) is documented. After that, drug will be discontinued. If participant has \<30% PSA decline, patient goes off study.
Study: NCT01291186
Drug: BPV6NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: intrathecal bupivacaine 6 mg for BMI less than 27.5 kg/m2
Study: NCT04308174
Drug: Gem/Cis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant Gemcitabine/Cisplatin
Study: NCT01291186
Drug: BPV7NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: intrathecal bupivacaine 7 mg for BMI less than 27.5 kg/m2
Study: NCT01291186
Drug: BPV8NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: intrathecal bupivacaine 8 mg for BMI less than 27.5 kg/m2
Study: NCT01291186
Drug: BPV9NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: intrathecal bupivacaine 9 mg for BMI less than 27.5 kg/m2
Study: NCT01291186
Drug: BPV10NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: intrathecal bupivacaine 10 mg for BMI less than 27.5 kg/m2
Study: NCT01291186
Drug: BPV11NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: intrathecal bupivacaine 11 mg for BMI less than 27.5 kg/m2
Study: NCT01291186
Drug: BPV10O
Approvals — FDA: no, EMA: no, PMDA: no
Description: intrathecal bupivacaine 10 mg for BMI over 27.5 kg/m2
Study: NCT01291186
Drug: BPV11O
Approvals — FDA: no, EMA: no, PMDA: no
Description: intrathecal bupivacaine 11 mg for BMI over 27.5 kg/m2
Study: NCT02215434
Drug: Testosterone, Transdermal, Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 0.5% testosterone Biolipid/B2
Study: NCT03661879
Drug: NNC9204-1706
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NNC9204-1706 subcutaneous (s.c., under the skin) injection(s) once daily (OD) for 10 weeks. They will either receive the same dose throughout the trial, or the dose will be escalated over a period of 1-3 weeks and continued for at least 7 weeks at the same dose.
Study: NCT03661879
Drug: Placebo (NNC9204-1706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo (NNC9204-1706) s.c., injection(s) OD for 10 weeks.
Study: NCT03131648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains the same excipients, in the same concentration only lacking tralokinumab
Study: NCT04401267
Drug: Intensive Antihypertensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receives intensive antihypertensive therapy
Study: NCT04401267
Drug: Conventional Antihypertensive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receives conventional antihypertensive therapy
Study: NCT03359473
Drug: GSK2881078
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2881078 will be available as capsules for oral administration. GSK2881078 will be administered once daily by the oral route at a dose of 1 mg and 2mg to post-menopausal female subjects and male subjects, respectively.
Study: NCT03359473
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered two capsules of GSK2881078 matching placebo once daily by the oral route.
Study: NCT00568516
Drug: ASP3550
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous administration
Study: NCT04653467
Drug: GLPG4399 oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG4399 for oral administration
Study: NCT04653467
Drug: GLPG4399 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG4399 for oral administration
Study: NCT04653467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral suspension
Study: NCT00740610
Drug: GS-9450 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match GS-9450 administered orally once daily
Study: NCT01610284
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM120 100 mg once daily
Study: NCT01610284
Drug: BKM120 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM120 matching placebo, once daily
Study: NCT00206232
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Research subjects are randomized to placebo versus spironolactone 25mg daily and followed for 6 months.
Study: NCT04554056
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor
Study: NCT00484744
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00484744
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02816567
Drug: placebo - isotonic saline serum
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02816567
Drug: sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01287182
Drug: Ateronon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ateronon daily for 3 months
Study: NCT02854722
Drug: Deferasirox and calcium-vitamin D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: deferasirox and calcium-vitamin D3 Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.~Calcium 500 mg and vitamin D3 800 IU should also be taken daily as a basic therapy.
Study: NCT02854722
Drug: Calcium-vitamin D3
Normalized name: Calcium/Cholecalciferol 600 MG-5 MCG Oral Capsule, Liquid Filled [CALCIUM-VITAMIN D3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.
Study: NCT01508923
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
Study: NCT02536404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01125358
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, twice daily for up to 7 weeks of treatment
Study: NCT04332835
Drug: Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy defined by institutional protocol.
Study: NCT04003103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules taken by mouth.
Study: NCT04311359
Drug: Drugs, Generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: All drugs having 19 or more Brain Oedema cases reported to the FAERS database
Study: NCT00956709
Drug: levobupivacaïne 0,5 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 %
Study: NCT00956709
Drug: ropivacaïne 0,5 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mL de ropivacaïne 0,5 %
Study: NCT00693056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (w/o API)
Study: NCT00693056
Drug: RX-10100 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/dose of RX-10100
Study: NCT01762020
Drug: Standard Preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard creams
Study: NCT01587898
Drug: GSK1278863
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT00578760
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: OD for course of cisplatin chemotherapy
Study: NCT04134260
Drug: Hormone Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive hormone therapy
Study: NCT04059900
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals
Study: NCT02282241
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02080273
Drug: Colgate Total toothpaste
Normalized name: Colgate Total Toothpaste Whitening
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.32% sodium fluoride (1450 ppm NaF) and 0.3% triclosan. Colgate Total toothpaste is the active comparator toothpaste
Study: NCT02080273
Drug: Parodontax toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1400 ppm sodium fluoride (NaF), Parodontax toothpaste is the active comparator toothpaste
Study: NCT00119678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable, intravenous, 0 mg, every 28 days, 12 months
Study: NCT02496780
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once or 3x daily
Study: NCT03376321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
Study: NCT00313781
Drug: CP-751,871
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-750,871 is administered intravenously at a dose of 20 mg/kg on day 1 of each 21-day cycle (for patient convenience and logistical management, the dose of CP-751,871 may be deferred up to 7 days).
Study: NCT01842516
Drug: LCB01-0371 800mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCB0-0371 800mg
Study: NCT01842516
Drug: LCB01-0371 1200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCB01-0371 1200mg
Study: NCT01842516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00329758
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg oral, during 10 days
Study: NCT04139993
Drug: Microbiota-based Formulation RBX7455
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00329758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00744302
Drug: physiological (1.25 mmol/L ) calcium dialysate
Normalized name: DIALYSATE,DUOSOL BICARBONATE 25 W/O CALCIUM SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using the physiological calcium dialysate (1.25 mmol/L calcium dialysate)for Stable haemodialysis treatment for more than 3 months, undergoing 2 to 3 times haemodialysis a week for 4 to 5 hours per session
Study: NCT00154323
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02537288
Drug: Placebo (for fedovapagon)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00877123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: similar placebo once a month for three consecutive months
Study: NCT05504967
Drug: Oradexon
Approvals — FDA: no, EMA: no, PMDA: no
Description: With a syringe aspirate 2.5 ml of a 5mg/ml dexamethasone solution, for a total of 12.5mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
Study: NCT00924573
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT02113397
Drug: TOBI™ Podhaler™ 112 mg inhaled twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02578043
Drug: Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% (Taro Pharmaceuticals Inc.)
Study: NCT02578043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
Study: NCT01347983
Drug: Tocilizumab+Methotrexate(MTX)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab: 8 mg/kg every 4 weeks, IV infusion Methotrexate: 10-20 mg/week
Study: NCT02834754
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Currently there are no clinical guidelines and no standard of care for the maintenance of surgically induced remission. There are no medications that have consistently been proven to be efficacious at preventing recurrent Crohn's disease and as such, no active equivalent arm is being used. Due to the lack of effective prophylactic therapy, many physicians and patients opt not to initiate medical therapy after surgery, rather wait until Crohn's disease recurs, or wait to perform a post-operative colonoscopy within 6-12 months of surgery, and decide on initiating Crohn's disease therapy based on endoscopic Rutgeerts; score. Therefore, acknowledging that many patients are not administered post-operative maintenance medications, we feel the placebo arm is justified.
Study: NCT01809639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard placebo
Study: NCT03836001
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is a tablet that looks like a drug but has no drug or other active ingredient in it.
Study: NCT00392379
Drug: Placebo lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenge
Study: NCT02971033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants assigned to this intervention will receive placebo every day for 12 weeks
Study: NCT02060916
Drug: PAZ320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-center pilot study, open label dose escalation design
Study: NCT01765010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04564638
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04269031
Drug: AZD2373 subcutaneous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).
Study: NCT04269031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.
Study: NCT03252015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01273584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo maximum dosage 2 tablets 3 times a day ( with meals) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
Study: NCT00158132
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills
Study: NCT01543581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02207946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study: NCT01998659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drinking solution
Study: NCT02304302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identically looking placebo capsules bid (after a four-week regimen designed to mimic standard dose titration protocol)
Study: NCT03803514
Drug: Recombinant EPO
Normalized name: EPOETIN ALFA,RECOMBINANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-epoetin (Recormon, Roche). Dosage was performed according to current recommendations.
Study: NCT01516684
Drug: placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given topically
Study: NCT01516684
Drug: fentanyl citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01860690
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg / meter squer Intramuscular (IM) MTX.
Study: NCT03310307
Drug: Vit D
Normalized name: Tri-Vit Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU
Study: NCT00371553
Drug: SU011248 (Sunitinib)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04686058
Drug: Pethidine Hydrochloride 50 Mg/mL Solution for Injection
Normalized name: Pethidine hydrochloride 50 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01362010
Drug: Topical Minocycline Foam FXFM244
Normalized name: minocycline Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically applied once a day.
Study: NCT00990418
Drug: Separated (Two Part) E-TRANS (fentanyl HCl) System; Integrated E-TRANS (fentanyl HCl) System
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01265264
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose administered daily for 84 days.
Study: NCT02351427
Drug: Steroid
Normalized name: Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators administer steroid in both groups for conventional treatment of acute cellular rejection.
Study: NCT01702636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01848041
Drug: RVL-1201 Vehicle Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVL-1201 Vehicle Placebo
Study: NCT00730067
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet with Laetose mono hydrat, talc,Potato tarch, Gelatin, Magnesium stearate.
Study: NCT01966107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose matched placebo, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
Study: NCT00839176
Drug: RX-10100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release tablet, 5\~15mg, twice day (morning \& evening) at least 30 min before meal, 8 weeks
Study: NCT00532779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01457352
Drug: SPARC0921
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01457352
Drug: Placebo0921
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03459391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.